Correction to: Burden of disease in myasthenia gravis: taking the patient’s perspective

Lehnerer, Sophie; Jacobi, Jonas; Schilling, Ralph; Grittner, Ulrike; Marbin, Derin; Gerischer, Lea; Stascheit, Frauke; Krause, Maike; Höffmann, Sarah; Meisel, Andreas

doi:10.1007/s00415-022-11290-w

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myasthenia gravis (MG) is a rare autoimmune disease targeting the neuromuscular junction, leading to fatigable muscle weakness that can manifest as ptosis, diplopia, dysarthria, dysphonia, dysphagia, extremity weakness and dyspnoea due to respiratory muscle weakness 1. The patient burden is significant and may impact nearly every aspect of life, including physical functioning, emotional well-being, relationships, family planning and ability to work 2. In patients with acetylcholine receptor antibody (AChRAb)-positive disease, conventional therapeutic strategies primarily include symptomatic treatment with acetylcholinesterase inhibitors, along with corticosteroids and steroid-sparing immunosuppressive agents, complement inhibitors and thymectomy 3–5.…”

Section: Introductionmentioning

confidence: 99%

“… 1 The patient burden is significant and may impact nearly every aspect of life, including physical functioning, emotional well-being, relationships, family planning and ability to work. 2 In patients with acetylcholine receptor antibody (AChRAb)-positive disease, conventional therapeutic strategies primarily include symptomatic treatment with acetylcholinesterase inhibitors, along with corticosteroids and steroid-sparing immunosuppressive agents, complement inhibitors and thymectomy. 3–5 Plasma exchange (PLEX) and intravenous immunoglobulin are used primarily to treat myasthenic worsening or exacerbation/crisis.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial

Benatar,

Wiendl,

Nowak

et al. 2024

BMJ Neurol Open

View full text Add to dashboard Cite

IntroductionBatoclimab, a fully human monoclonal antibody that inhibits the neonatal fragment crystallisable receptor, has shown promising phase 2 clinical trial results in patients with generalised myasthenia gravis (gMG).Methods and analysisIn this phase 3, randomised, quadruple-blind, placebo-controlled study, adults with gMG will be randomised 1:1:1 to induction therapy with batoclimab 680 mg, batoclimab 340 mg, or placebo, administered once weekly (QW) for 12 weeks as a subcutaneous injection. The primary endpoint is the change from baseline to week 12 on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score. Batoclimab-treated patients achieving a ≥2-point improvement from baseline on MG-ADL at week 10 or week 12 will be re-randomised to maintenance treatment with batoclimab 340 mg QW, batoclimab 340 mg every other week (Q2W), or placebo for 12 weeks; batoclimab-treated patients with a <2-point improvement at week 10 and week 12 will be switched to placebo for the maintenance period and discontinued thereafter. Placebo-treated patients from the induction period will be re-randomised to batoclimab 340 mg QW or Q2W in the maintenance period. All patients who complete the maintenance period and achieve a ≥2-point improvement from baseline in MG-ADL during ≥1 of the final 2 visits of the induction and/or maintenance periods will continue their current batoclimab dose (or switch to batoclimab 340 mg QW for those on placebo) for a 52-week long-term extension (LTE-1). Patients who complete LTE-1 may enter a second, optional 52-week LTE (LTE-2).Ethics and disseminationThis trial is being conducted in accordance with the International Council for Harmonisation Guideline for Good Clinical Practice, the Declaration of Helsinki, and each site’s Institutional Review Board/Independent Ethics Committee. All patients must provide written informed consent. Results from this study will be published in peer-reviewed journals and presented at national and global conferences.Trial registration numberNCT05403541.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial

Benatar,

Wiendl,

Nowak

et al. 2024

BMJ Neurol Open

View full text Add to dashboard Cite

show abstract

Association between the patients’ symptom burden and their family caregivers’ benefit finding in non-small cell lung cancer receiving combined chemotherapy

Zhu

Shi

et al. 2023

Support Care Cancer

View full text Add to dashboard Cite

Environmental factors affecting the risk of generalization for ocular-onset myasthenia gravis: a nationwide cohort study

Wang,

Zhou,

Chen

et al. 2023

QJM: An International Journal of Medicine

View full text Add to dashboard Cite

Summary Background The environmental effects on the prognosis of ocular myasthenia gravis (OMG) remain largely unexplored. Aim To investigate the association between specific environmental factors and the generalization of OMG. Design The cohort study was conducted in China based on a nationwide multicenter database. Methods Adult patients with OMG at onset, who were followed up for at least 2 years until May 2022, were included. We collected data on demographic and clinical factors, as well as environmental factors, including latitude, socioeconomic status (per capita disposable income [PDI] at provincial level and education) and smoking. The study outcome was the time to the development of generalized myasthenia gravis (GMG). Cox models were employed to examine the association between environmental exposures and generalization. Restricted cubic spline was used to model the association of latitude with generalization risk. Results A total of 1396 participants were included. During a median follow-up of 5.15 (IQR 3.37-9.03) years, 735 patients developed GMG within a median of 5.69 (IQR 1.10-15.66) years. Latitude of 20-50°N showed a U-shaped relation with generalization risk, with the lowest risk at around 30°N; both higher and lower latitudes were associated with the increased risk (P for non-linearity <0.001). Living in areas with lower PDI had 1.28-2.11 times higher risk of generalization. No significant association was observed with education or smoking. Conclusions Latitude and provincial-level PDI were associated with the generalization of OMG in China. Further studies are warranted to validate our findings and investigate their potential applications in clinical practice and health policy.

show abstract

Correction to: Burden of disease in myasthenia gravis: taking the patient’s perspective

Cited by 4 publications

References 0 publications

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial

Association between the patients’ symptom burden and their family caregivers’ benefit finding in non-small cell lung cancer receiving combined chemotherapy

Environmental factors affecting the risk of generalization for ocular-onset myasthenia gravis: a nationwide cohort study

Contact Info

Product

Resources

About